SCHEDULE 13G/A: Wellington Management Group Maintains Significant Stake in Apellis Pharmaceuticals

Wellington Management Group LLP and its affiliates have reported a continued beneficial ownership of 9.5% of Apellis Pharmaceuticals, Inc.'s common stock as of December 31, 2024.

Summary

• Wellington Management Group LLP and its affiliated entities (Wellington Group Holdings LLP, Wellington Investment Advisors Holdings LLP, and Wellington Management Company LLP) collectively beneficially own 11,833,409 shares of Apellis Pharmaceuticals, Inc. common stock.
• This represents 9.5% of the total outstanding common stock of Apellis Pharmaceuticals, Inc.
• The filing date for this Schedule 13G Amendment No. 8 is February 10, 2025, reporting ownership as of December 31, 2024.
• The shares are held in the ordinary course of business by clients of Wellington's investment advisers, not for the purpose of changing or influencing control of the issuer.
• Wellington Management Company LLP specifically reported shared voting power over 11,382,754 shares and shared dispositive power over 11,603,969 shares, representing 9.3% of the class.
• The broader Wellington Management Group LLP and its direct holding affiliates reported shared voting power over 11,418,239 shares and shared dispositive power over 11,833,409 shares, representing 9.5% of the class.
• One specific client, Vanguard Health Care Fund, is noted as having the right or power with respect to more than five percent of this class of securities.

Sentiment

Score: 7

Explanation: The filing indicates a stable, significant institutional holding by a reputable asset manager, suggesting continued confidence in the company without any negative implications. It's a routine disclosure of a large, passive investment.

Positives

• Continued significant institutional ownership by a major asset manager like Wellington Management Group, indicating confidence in Apellis Pharmaceuticals.
• The holding is for investment purposes in the ordinary course of business, not for activist intent, suggesting a stable, long-term investment.

Future Outlook

This Schedule 13G filing does not contain forward-looking statements or guidance regarding Apellis Pharmaceuticals, Inc.'s future outlook, as its purpose is solely to disclose beneficial ownership.

Industry Context

This filing indicates continued significant institutional investment in the biotechnology and pharmaceutical sector, specifically in Apellis Pharmaceuticals, Inc., by a prominent asset management firm. Such large holdings by institutional investors are common in the industry, reflecting long-term investment strategies.

Comparison to Industry Standards

• This document, a Schedule 13G, is a standard regulatory filing for disclosing beneficial ownership exceeding 5%. It does not provide financial or operational data for comparison to industry standards or specific comparable companies or projects. Its purpose is limited to ownership disclosure.

Stakeholder Impact

• Shareholders: The continued significant holding by Wellington Management Group may be viewed positively, signaling institutional confidence and potentially contributing to share price stability.

Key Dates

Keywords

Apellis Pharmaceuticals, Wellington Management, Schedule 13G, Common Stock, Institutional Ownership, Beneficial Ownership, SEC Filing, Biotechnology, Pharmaceutical